BC
AMRX icon

Brinker Capital’s Amneal Pharmaceuticals AMRX Stock Holding History

Brinker Capital’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-21,110
Closed -$299K – 935
2019
Q1 		$299K Buy
21,110
+2,105
+11% +$27.8K 0.01% 803
2018
Q4 		$257K Sell
19,005
-4,345
-19% -$78.3K 0.01% 777
2018
Q3 		$518K Buy
23,350
+1,397
+6% +$29.4K 0.02% 701
2018
Q2 		$360K Buy
+21,953
New +$385K 0.01% 809

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brinker Capital's AMRX Position: Q2 2019 in Review

Brinker Capital sold out of Amneal Pharmaceuticals (AMRX) in Q2 2019, closing a stake of 21,110 shares — an estimated $299K sold.

Brinker Capital first reported a position in AMRX in Q2 2018 and held it in 4 quarters. The position peaked at $518K in Q3 2018. 129 funds tracked by Wall St. Rank hold AMRX as of Q2 2019.

  • Brinker Capital reported no remaining Amneal Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Brinker Capital sold 21,110 Amneal Pharmaceuticals shares in Q2 2019, an estimated $299K.
  • Brinker Capital first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Brinker Capital's Amneal Pharmaceuticals position peaked at $518K in Q3 2018.
  • 129 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2019.

Based on Brinker Capital's 13F filing for Q2 2019, filed 12 Aug 2019.